July 14, 2025Expert Opinion on Investigational DrugsOpen Access

Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions

View Full Paper

Ask AI

Bookmark

Authors

PRPaul G. RichardsonHarvard University EOElisabeth K. O’DonnellHarvard University POPeter O’GormanMater Misericordiae University Hospital

Discussion

Member takes

Implication

Clinical trials demonstrate isatuximab enhances outcomes for newly diagnosed multiple myeloma patients, suggesting its potential in various treatment combinations.

Key Points

Isatuximab shows significant efficacy when added to standard therapies for multiple myeloma treatment.
Pivotal Phase 3 and 2 trials highlight safety and effectiveness for both transplant-ineligible and transplant-eligible patients.
Innovative dosing strategies of bortezomib and dexamethasone optimize isatuximab-based treatment regimens.
Emerging real-world evidence supports isatuximab's role in improving outcomes for relapsed/refractory multiple myeloma.

Cite This Study

Richardson et al. (2025) studied this question.

synapsesocial.com/papers/689a02b6e6551bb0af8cc2ec https://doi.org/10.1080/13543784.2025.2532446

View Full Paper

Ask AI

Bookmark

Implication

Clinical trials demonstrate isatuximab enhances outcomes for newly diagnosed multiple myeloma patients, suggesting its potential in various treatment combinations.

Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions

Discussion

Member takes

Implication

Key Points

Cite This Study

Isatuximab for the treatment of multiple myeloma: current clinical advances and future directions

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider